Evidence map›Paper›PMID 19523538›Full record

ArticleClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2009

Medication usage and the risk of neoplasia in patients with Barrett's esophagus.

Dang M Nguyen, Hashem B El-Serag, Louise Henderson, Daniel Stein, Achyut Bhattacharyya, Richard E Sampliner

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 11 pooled it
15.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 11 syntheses or guidelines pooled it, 159 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. ACG Clinical Guideline: Diagnosis and Management of Barrett's Esophagus.The American journal of gastroenterology · 2016
    Guideline
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Statins are associated with reduced risk of esophageal cancer, particularly in patients with Barrett's esophagus: a systematic review and meta-analysis.Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2013
    Pooled it
  11. Pooled it
  12. Trial
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Statins as Potential Therapeutics for Esophageal Cancer.Journal of gastrointestinal cancer · 2021
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Dang M NguyenHouston Center for Quality of Care and Utilization Studies, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas, USA.
Hashem B El-Serag
Louise Henderson
Daniel Stein
Achyut Bhattacharyya
Richard E Sampliner
University of Arizona · USMichael E. DeBakey VA Medical Center · USBaylor College of Medicine · US

Funding

Obesity, H pylori and Risk of Barrett's EsophagusR01CA116845 · NCI · BAYLOR COLLEGE OF MEDICINE · PI EL-SERAG, HASHEM B · 2007 to 2011
$2.8M
Epidemiology and Outcomes of Digestive and Liver Diseases: A Mentoring ProgramK24DK078154 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI EL-SERAG, HASHEM B · 2007 to 2016
$1.1M
NCI NIH HHS 5R01CA116845-04NCI NIH HHS R01 CA116845NIDDK NIH HHS DK 563338NIDDK NIH HHS K24 DK078154NIDDK NIH HHS K24DK078154-03
6 · The paper itself

Abstract

BACKGROUND &

aimsExperimental evidence indicates that proton pump inhibitors (PPIs), nonsteroidal anti-inflammatory drugs (NSAIDs)/aspirin, and statins can protect patients with Barrett's esophagus (BE) from developing neoplasias. However, only limited data are available on chemoprevention in patients with BE.

methodsA retrospective observational study was performed using data from patients with documented BE. Prescription information was collected from pharmacy records. Cox regression analyses were performed to examine the association between prescriptions for PPIs, NSAIDs/aspirin, or statins and the risk of developing esophageal dysplasia or adenocarcinoma during follow-up (from 1982 to 2005).

resultsWe examined 344 patients diagnosed with BE (mean age 61 years, 90.4% Caucasian, 94.2% male). After BE diagnosis, 67.2% of the patients were prescribed PPIs for a mean duration of 5.1 years; 49.1% were prescribed NSAIDs for a mean duration of 3.6 years, and 25.3% were prescribed statins for a mean duration of 2.8 years. During 2620 patient-years, high grade dysplasia or esophageal adenocarcinoma developed in 33 patients. PPI treatment after BE diagnosis was associated with a reduced risk of high grade dysplasia or cancer; this association persisted after adjustment for gender, age, and the length of BE. NSAID and/or aspirin therapy were associated with a nonsignificant trend toward lower incidence of high grade dysplasia or esophageal cancer.

conclusionsPPI therapy reduces the risk of neoplasms in patients with BE. NSAIDs/aspirin appear to reduce cancer risk whereas statin use is not significantly associated with the risk of neoplasia in patients with BE.

Indexed as

Drug MonitoringAgedAnti-Inflammatory Agents, Non-SteroidalBarrett EsophagusEsophageal NeoplasmsFemaleHumansMaleMiddle AgedProton Pump InhibitorsRetrospective StudiesRisk FactorsAnti-Inflammatory Agents, Non-SteroidalProton Pump Inhibitors

Identifiers

PMID19523538
PMCPMC2789910
OpenAlexW2071302779

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.